XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 1 filers reported holding XENON PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,644,189 | -17.2% | 106,680 | -6.7% | 2.95% | +4.9% |
| Q2 2023 | $4,403,630 | +7.6% | 114,380 | 0.0% | 2.81% | +1.0% |
| Q1 2023 | $4,093,660 | -9.2% | 114,380 | 0.0% | 2.79% | -10.3% |
| Q4 2022 | $4,510,003 | +9.2% | 114,380 | 0.0% | 3.11% | +17.9% |
| Q3 2022 | $4,129,000 | +18.7% | 114,380 | 0.0% | 2.64% | +10.3% |
| Q2 2022 | $3,479,000 | -42.5% | 114,380 | -42.2% | 2.39% | -16.7% |
| Q1 2022 | $6,049,000 | -2.2% | 197,880 | 0.0% | 2.87% | +56.9% |
| Q4 2021 | $6,182,000 | +104.4% | 197,880 | 0.0% | 1.83% | +88.9% |
| Q3 2021 | $3,024,000 | -17.9% | 197,880 | 0.0% | 0.97% | -15.5% |
| Q2 2021 | $3,685,000 | – | 197,880 | – | 1.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
| COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
| TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
| Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
| Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
| GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
| DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
| Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
| Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
| Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |